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http://dx.doi.org/10.1016/j.jfma.201
0929-6646/Copyright ª 2014, ElsevierExtracorporeal membrane oxygenation (ECMO) has been utilized for critically ill patients such
as patients with postcardiotomy cardiogenic shock or life-threatening respiratory failure.
Acute kidney injury (AKI) that develops during ECMO is associated with a very poor outcome,
possibly because of accumulated extravascular water causing interstitial overload, impaired
oxygen transport through tissues, and increased extravascular lung water volume with
impaired O2 transport. Increased water is associated with subsequent organ dysfunction,
particularly of the heart, lungs, and brain. Based on single-center studies, the incidence of
AKI is 70e85% in ECMO patients. Therefore, renal replacement therapy is required in approx-
imately 50% of these patients. This review summarizes three modalities that can be used to
introduce renal replacement therapy to patients on ECMO, the pathophysiology of AKI in ECMO,
and the impact of AKI on mortality. This review also identifies specific research-focused ques-
tions that need to be addressed to predict AKI early and to improve outcomes in this at-risk
adult population.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.clare no conflicts of interest.
f Critical Care Nephrology,
ung Memorial Hospital, 199
wan.
University College of Medi-
i 105, Taiwan.
.cgmh.org.tw (Y.-C. Chen),
4.04.006
Taiwan LLC & Formosan MedicalIntroduction
Critically ill patients frequently require mechanical venti-
lation, circulatory support, and other assistant devices.
Extracorporeal membrane oxygenation (ECMO) is recom-
mended for patients with acute, potentially reversible,
life-threatening respiratory failure that is unresponsive to
conventional therapy. Treatment by ECMO may also be
effective in patients with severe reversible myocardial
dysfunction (e.g., myocarditis or postoperative cardiogenicAssociation. All rights reserved.
AKI in ECMO 779shock) or acute respiratory distress syndrome (ARDS); it
may also provide temporary support prior to another
treatment modality (e.g., heart transplant).1e5 The type of
ECMO administered will depend on the patient’s underlying
cardiac function. Venovenous (VV) ECMO (VV-ECMO) is
usually administered for isolated respiratory failure,
whereas venoarterial (VA) ECMO (VA-ECMO; i.e., full car-
diopulmonary bypass) is administered for combined cardiac
and respiratory failure. Table 1 lists the indications and
contraindications for VV-ECMO and VA-ECMO support.6,7
The algorithm in Fig. 1 simplifies the understanding about
the choice of the type of VV-ECMO or VA-ECMO in clinical
settings. Circuit flow may be achieved by a centrifugal or
roller pump or by a patient’s arteriovenous (AV) pressure
gradient (i.e., pumpless). The AV-ECMO system is charac-
terized by a membrane gas exchange device integrated into
a pumpless AV circuit, which is established by theTable 1 Indications and contraindications for VA-ECMO and VV-
Indications
VA-ECMO
 Cardiogenic shock: AMI and complications (e.g., wall rupture, p
to conventional therapy such as IABP
 Postcardiac surgery: unable to wean safely from cardiopulmona
 Drug overdose with profound cardiac depression
 Acute myocarditis
 Early graft failure: postheart transplant or postheart-lung trans
 As a bridge to cardiac transplantation
 Intractable arrhythmia
 Pulmonary hypertension (after pulmonary endarterectomy)
VV-ECMO
 Any potentially reversible acute respiratory failure
 ARDS that is associated with pneumonia (viral or bacterial)
 Failed lung transplant graft
 Trauma (pulmonary contusion)
 Pulmonary embolism (if patient has acceptable cardiac functio
Contraindications
Contraindications to all forms of ECMO
 Any condition or organ dysfunction that would limit the likeliho
brain injury or untreatable metastatic cancer
 Patient has contraindications to anticoagulation therapy
 ECMO as a bridge to heart or lung transplantation if transplant
 Limited vascular access
VA-ECMO
 Severe aortic regurgitation
 Aortic dissections
VV-ECMO
 Severe pulmonary hypertension (mPAP > 50 mmHg)
 Severe right or left heart failure (EF < 25%)
 Cardiac arrest
AMI Z acute myocardial infarction; ARDS Z acute respiratory distr
EF Z ejection fraction; IABP Z intra-aortic balloon pump; mP
VF Z ventricular fibrillation; VT Z ventricular tachycardia; VV Z vecannulation of the femoral artery and vein. The circuit
provides a small amount of oxygenation, but mostly carbon
dioxide removal, as the arterial blood is returned to the
venous side. Arteriovenous ECMO is primarily useful in pa-
tients with severe hypercapnia, respiratory acidosis, and
moderate hypoxemia. The pumpless circuit makes this de-
vice simple to use, but cardiac function must be preserved
for the patient’s blood to be effectively pumped (i.e., a
cardiac index of at least 2.5 L/minute/m2). However, high
mortality has been reported in ARDS patients who are on
AV-ECMO and some patients may require conversion from
AV-ECMO to VV-ECMO or to VA-ECMO.8,9
Acute kidney injury (AKI) that develops during ECMO is
associated with very poor outcome (i.e., patients who
develop AKI have high mortality rates and resource utili-
zation).1,2,10 Most studies demonstrate that patients
exhibiting renal failure signs [e.g., increased serumECMO.
apillary muscle rupture, refractory VT/VF) that are refractory
ry bypass using conventional supports
plant
n)
od of overall benefit from ECMO such as severe, irreversible
ation will not be considered
ess syndrome; ECMO Z extracorporeal membrane oxygenation;
AP Z mean pulmonary artery pressure; VA Z venoarterial;
novenous.
Figure 1 The choice of extracorporeal membrane oxygenation. ECMO Z extracorporeal membrane oxygenation;
VA Z venoarterial; VV Z venovenous.
780 Y.-C. Chen et al.creatinine (SCr) level and/or oliguria] typically respond
poorly to ECMO. Acute kidney injury and its complications
such as volume overload and azotemia are common in this
situation. Some epidemiological studies show that more
than 75% of the patients requiring ECMO therapy develop
AKI. Renal replacement therapy (RRT) is required in
approximately 50% of these patients. The management of
patients with AKI is principally supportive with RRT indi-
cated for patients with severe kidney injury. Table 2 lists
the interaction between the RRT circuit and the ECMO
circuit and the indications for initiating dialysis.11,12 Fig. 2
illustrates the inclusion of continuous renal replacement
therapy (CRRT) device in the peripheral VA-ECMO circuit.
Pathophysiology of AKI in ECMO
Prior to the initiation of ECMO, the etiology of AKI in these
patients is almost always because of multiple factors such
as sepsis, low cardiac output syndrome, exposure to
nephrotoxic agents, and high intrathoracic pressures. Acute
kidney injury, a manifestation of multiple organ system
failure (OSF), is associated with underlying decompensated
heart failure and sepsis and is aggravated by complications
such as surgical site bleeding during ECMO support.13
Whether AKI directly produces these adverse outcomes
remains unclear; however, increased infection and new-
onset sepsis, congestive heart failure, and fluid overload
may contribute to AKI.14
Hypotension is associated with worsening renal function
for patients on ECMO. Damaged cardiac function (which
creates a condition of low cardiac output and therefore
hypoperfusion), if not promptly corrected, can allow pre-
renal AKI to progress to intrinsic AKI and cortical necrosis,
which results in irreversible loss of renal function.15
During the first 24e48 h on ECMO, oliguria and acute
tubular necrosis associated with capillary leakage and
intravascular volume depletion are common because ECMO
triggers an acute inflammatory-like reaction. Decreased
urine output (UO) represents renal hypoperfusion resultingfrom low cardiac output (i.e., cardiogenic shock) or sys-
temic vasodilatation (i.e., sepsis). Decreased UO also leads
to fluid overload that impairs tissue oxygenation and oxy-
gen transport in the lungs. This eventually leads to organ
dysfunction of the heart, brain, and lungs. Fluid overload
further increases preload and may contribute to circulatory
failure. Circulatory failure may further aggravate in-
hospital mortality.1,8,16,17
In VA ECMO, cardiac output is a mixture of native cardiac
(i.e., pulsatile) flow and ECMO pump (i.e., nonpulsatile)
flow. The mechanical flow may be nonpulsatile, although
institution of VA-ECMO usually raises blood pressure and
flow to the vital organs, including the kidneys. Venovenous
ECMO maintains native pulsatile cardiac output, and
changes in renal perfusion are less in VA-ECMO. After the
initiation of ECMO, oxygenation improves, oxygen con-
sumption reduces, and hemodynamics improves in most
patients. The initiation of ECMO (especially in neonates and
children) with subsequent adjustments in vasopressor drugs
and inotropic drugs can nevertheless cause rapid hemody-
namic fluctuations that alter renal blood flow and lead to
ischemia- and reperfusion-associated AKI.18,19
Other factors associated with ECMO initiation predispose
patients to incident AKI or exacerbation of AKI. Blood
exposure to artificial surfaces causes systemic inflammation
and hemoglobinuria-induced renal injury due to different
degrees of hemolysis occur in the extracorporeal circuit.19
Impact of AKI on mortality
Patients on ECMO
Lin et al1 retrospectively applied the risk of renal failure,
injury to the kidney, failure of kidney function, loss of
kidney function, and end-stage renal failure (RIFLE) criteria
to evaluate 46 critically ill patients treated by ECMO. Most
of them had postcardiotomy cardiogenic shock. In 2004, the
Acute Dialysis Quality Initiative Group published the RIFLE
criteria in an attempt to standardize AKI research.20 It
Table 2 Modalities of RRT on ECMO and indications.
Modalities of ECMO plus RRT
 A double-lumen catheter can be used to connect the RRT circuit to part of the ECMO circuit
 A series circuit (e.g., SCUF or CAVH) can be used
 A connection can be created between the RRT machine and the ECMO circuit
Indications for ECMO plus RRT
 Anuria (>12 h), unresponsive to high doses of diuretics
 Oliguria (>12 h), unresponsive to high doses of diuretics
 AKI in progression
 Oliguria/AKI with metabolic acidosis
 Oliguria/AKI with hyperkalemia
 Oliguria/AKI with pulmonary edema
AKI Z acute kidney injury; CAVH Z continuous arteriovenous hemofiltration; ECMO Z extracorporeal membrane oxygenation;
RRT Z renal replacement therapy; SCUF Z slow continuous ultrafiltration.
AKI in ECMO 781classified AKI into three categories (risk, injury, and fail-
ure), based on the status of the SCr level and UO. The RIFLE
criteria were assessed only during the first day of ECMO
support. A progressive and significant increase in mortality
among all patients was associated with increasing RIFLE
categories. At the 6-month follow-up, cumulative survival
rates differed significantly (p < 0.05) for non-AKI versus
RIFLE-Injury and RIFLE-Failure, and for RIFLE-Risk versus
RIFLE-Failure.Figure 2 Incorporation of an integrated continuous renal replace
oxygenation (ECMO) circuit. Blood is delivered to the CRRT device f
the postpump limb of roller pump circuits or (B) to the venous limThe authors further reviewed the medical records of 78
critical ill patients on ECMO support.2 The RIFLE criteria
classified 78.2% of the patients as having AKI. Multivariate
analysis indicated that Acute Physiology, Age, Chronic
Health Evaluation (APACHE) IV, and the RIFLE classification
had independent prognostic significance (Table 3).
The RIFLE criteria can precisely predict hospital mor-
tality in this subset of critically ill patients on ECMO Day 1.
The influence of other factors (e.g., advanced age, type ofment therapy (CRRT) system with an extracorporeal membrane
rom the postpump limb of the ECMO circuit and returned (A) to
b of centrifugal pump circuits.
Table 3 Variables predicting in-hospital mortality at different stages of ECMO treatment.
n Independent predictors Study period Refs
On ECMO 78  APACHE IV
 RIFLE
March 2002eOctober 2005 2
Post-ECMO 48-hour 102  AKIN48-hour
 Age
 GCS score on ECMO
March 2002eJanuary 2008 10
RRT on ECMO 123  Age
 MAP on RRT
 OSF number on RRT
March 2003eAugust 2010 11
Off ECMO 119  Daily UO on the second
day of ECMO removal (UO24e48 hour)
 MAP off ECMO
 SOFA off ECMO
July 2006eOctober 2010 16
ARDS on ECMO 81  APACHE II
 MAP
 Platelet count
 UO
May 2006eDecember 2011 32
AKIN Z Acute Kidney Injury Network; APACHE Z Acute Physiology, Age, Chronic Health Evaluation; ARDS Z acute respiratory distress
syndrome; ECMO Z extracorporeal membrane oxygenation; GCS Z Glasgow Coma Scale; MAP Z mean arterial pressure; OSF Z organ
system failure; RIFLEZ risk of renal failure, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage renal
failure; RRT Z renal replacement therapy; SOFA Z Sequential Organ Failure Assessment; UO Z urine output.
782 Y.-C. Chen et al.surgery, history of chronic disease, hemodynamics, neuro-
logical factors, or respiratory factors) on the morbidity and
mortality of critically ill patients on ECMO are not measured
by the RIFLE score. The failure to measure such extrarenal
parameters in the RIFLE classification may explain its
inferiority to APACHE IV, APACHE III, APACHE II, and
Sequential Organ Failure Assessment (SOFA) scores in
discriminative capability.2
Post-ECMO 48-hour
Chen et al10 evaluated the outcomes of 102 patients
treated with ECMO and identified the relationship between
prognosis and Acute Kidney Injury Network (AKIN) scores
obtained at pre-ECMO support (AKIN0-hour); and at
24 hours post-ECMO support (AKIN24-hour) and 48 hours
post-ECMO support (AKIN48-hour).10 In 2007, the AKIN group
proposed a modified version of the RIFLE criteria. In AKIN
stage-1 (analogous to RIFLE-Risk), a smaller change within
48 hours in the SCr leveld0.3 mg/dL (26.2 mmol/L) or
greaterdwas suggested as the AKI threshold. In addition,
patients receiving RRT were reclassified as AKIN stage-3
(i.e., RIFLE-Failure). Finally, the “loss” and “end-stage
kidney disease” categories were eliminated in the AKIN
classification.21 The overall in-hospital mortality rate was
57.8%. The AKIN0-hour, AKIN24-hour, and AKIN48-hour
scoring systems also had excellent areas under the
receiver operating characteristic curve (AUROCs)
(0.804  0.046, 0.811  0.045, and 0.858  0.040,
respectively). Furthermore, multiple logistic regression
analysis indicated that AKIN48-hour score, age, and Glas-
gow Coma Scale score on the Day 1 of intensive care unit
admission were independent risk factors for hospital mor-
tality (Table 3). Cumulative survival rates at the 6-month
follow up after hospital discharge differed significantly for
AKIN48-hour stage 0 versus AKIN48-hour stages 1, 2, and 3,and for AKIN48-hour stages 1 and 2 versus AKIN48-hour
stage 3 (p < 0.05). During ECMO support, the AKIN48-hour
scoring system proved to be a reproducible evaluation
tool with an excellent prognostic ability for these patients.
The AKIN group aimed to improve the sensitivity and
reproducibility of the AKI criteria and define the AKIN
classification. However, some studies indicate that the AKIN
criteria may not improve sensitivity and predictive abil-
ity.22e24 The AKIN stage-1 is notably similar to RIFLE-Risk,
but includes abrupt (i.e., within 48 hours) reduction in
kidney function (indicated by an increase in the SCr level of
0.3 mg/dL or greater). In addition, stage 3 encompasses
patients who require RRT at any stage. Emerging evidence
suggests that even small increases in SCr levels after car-
diac surgery significantly increase mortality. Several studies
document a high mortality rate for patients treated with
ECMO and RRT.1e3
RRT on ECMO
In a study by Morris et al,25 all 13 children managed with
ECMO and slow continuous ultrafiltration died. In such pa-
tients, a fatal outcome is often associated with the pro-
gression of conduction disturbance to electromechanical
dissociation and asystole.25 In a study by Balasubramanian
et al,26 30 pediatric surgical cardiac patients requiring RRT
while on ECMO had a high risk of hospital mortality. Kolovos
et al27 also demonstrated that children who underwent
postcardiotomy ECMO requiring hemofiltration had a mor-
tality rate five times that of patients without AKI. Wu et al12
proved that independent predictors for hospital mortality
among ECMO patients on dialysis were high central venous
pressure, high APACHE IV score when initializing dialysis,
and latency from hospital admission to dialysis.
In a previous study by our study group, 21 AKI patients
treated by ECMO and continuous arteriovenous
AKI in ECMO 783hemofiltration (CAVH) died during hospitalization.2 In a
subsequent study, two patients with myocardial dysfunc-
tion survived following ECMO and CAVH treatment.3 Early
diagnosis and aggressive treatment of patients with fewer
than three failed organs resulted in a favorable outcome.
Timely administration of ECMO and CAVH is effective in
supporting circulation and renal function for myocardial
dysfunction that is refractory to conservative treatment.
These will likely be the standard treatments in the near
future. These studies indicate that advanced cardiac fail-
ure may require more aggressive and earlier initiation of
ECMO support before AKI develops.
Tsai et al11 reviewed the medical records of 123 criti-
cally ill patients on ECMO plus CAVH support. The overall in-
hospital mortality rate was 85.4%. The most common con-
dition requiring ECMO plus CAVH support was cardiogenic
shock and anuria. The goodness-of-fit was good for OSF
number. The OSF number also had good AUROC curve
(0.758  0.057). Multiple logistic regression analysis also
indicated that age, mean arterial pressure (MAP), and OSF
number on the 1st day of ECMO plus CAVH were independent
risk factors for hospital mortality (Table 3). Cumulative
survival rates at the 6-month follow up after hospital
discharge differed significantly (p < 0.05) for patients with
an OSF number of 4 or less versus patients with OSF number
of 4 or greater.11
Survival when on ECMO generally decreases as the pa-
tient’s age increases. Nehra and colleagues28 reported a
bimodal distribution of survival with respect to patient age,
with the highest survival in groups aged 0e9 years and
30e39 years. This distribution was noted previously and has
been confirmed by data from the Extracorporeal Life Sup-
port Organization database.29 For patients treated with
ECMO and CAVH, Tsai et al11 adopted the best Youden index
and established a cut-off value of 50 years of age. Hospital
mortality rates differed significantly, according to the best
Youden index below and above the cutoff of 50 years of age
(75.4% vs. 93.9%, p Z 0.005).Patients off ECMO
Chang et al16 reviewed the medical records of 119 critically
ill patients who were successfully weaned from ECMO.
Successful weaning was defined as weaning from ECMO
support after a survival longer than 48 hours.16 The overall
in-hospital mortality rate was 26%. The most common
condition requiring ECMO support was cardiogenic shock. By
using the AUROC curve, the SOFA score displayed good
discriminative power (AUROC was 0.805  0.055;
p < 0.001). In addition, multiple logistic regression analysis
indicated that daily UO on the 2nd day of ECMO removal
(UO24e48 hour), MAP, and the SOFA score on the day of ECMO
removal were independent predictors of hospital mortality
(Table 3). Cumulative survival rates at the 6-month follow
up differed significantly for patients with a SOFA score of 13
or less, compared to the survival rate for patients with a
SOFA score greater than 13 (p < 0.001).
Urine volume is a more sensitive marker than the SCr
level for the early detection of AKI. Decreased urine volume
on the day of ECMO removal is attributed to decreased
cardiac output after decannulation, and is correlated withacute cardiorenal syndrome type 1.30 For patients with
improved systolic function, the urine volume may increase
gradually in the following days. For other patients,
decreased urine volume progresses and causes fluid over-
load, which likely increases preload and may contribute to
circulatory failure. In addition, loop diuretics were usually
prescribed for better diuresis in patients with decreased
urine volume. Metra et al31 identified the use of loop di-
uretics as a modifiable in-hospital determinant of acute
cardiorenal syndrome type 1, which probably occurs by
further activation of the renin-angiotensin-aldosterone
system and worsening of intrarenal hemodynamics. Circu-
latory failure may further aggravate in-hospital mortality.
For patients weaned from ECMO, Chang et al16 adopted the
best Youden index and established a cut-off urine volume of
1468 mL. Hospital mortality rates below and above the
cutoff value of 1468 mL of daily urine volume on the 2nd day
of ECMO removal were 59.5% (22 of 37 patients) and 12.5%
(9 of 72 patients; p < 0.001), respectively.16ECMO for ARDS
Hsiao et al32 reviewed the medical records of 81 ARDS pa-
tients after ECMO support. The overall in-hospital mortality
rate was 55.5%. A multiple logistic regression analysis
indicated that the APACHE II score, MAP, platelet count,
and UO on Day 1 of ECMO support were independent risk
factors for hospital mortality (Table 3). By using the AUROC
curve, UO obtained on the 1st day of ECMO support
demonstrated good discriminative power (AUROC was
0.754  0.056; p < 0.001). Urine output had the best
discriminative power, the best Youden index, and the
highest overall correctness of prediction. Cumulative sur-
vival rates at the 6-month follow up differed significantly
(p < 0.001) for a UO of 1432 mL or greater on Day 1 of ECMO
support versus the survival rate of patients with a UO of less
than 1432 mL on Day 1 of ECMO support. Urine output ob-
tained on the 1st day of ECMO is related to the severity of
the underlying critical illness affecting the ARDS patient.
Predicting the outcome after ARDS onset is difficult
because ARDS occurs in patients with various profiles and
diverse disease etiologies.33,34 The APACHE system assumes
that the core mission of intensive care is treating the dis-
ease and maintaining physiological homeostasis. Physio-
logical abnormalities are common among intensive care
unit patients, and the extent of derangement is an objec-
tive and reproducible measure of illness severity. The SOFA
score ignores diagnosis, age, and comorbid conditions. This
could, at least partially, explain the superiority of APACHE
II to SOFA.Future research needs
Renal failure is common in critically ill patients on ECMO. It
has an extremely high mortality rate. New classification
systems for AKI may enhance standardization of the diag-
nosis and staging of this clinical syndrome. Novel bio-
markers for the early diagnosis of AKI may represent a
breakthrough for cliniciansdif the biomarkers are accu-
rate, reproducible, and applicable in different settings.
784 Y.-C. Chen et al.There are no specific therapeutic interventions for patients
with established AKI.35e37
During ECMO support, the AKIN48-hour scoring system
proved to be a reproducible evaluation tool with an
excellent prognostic ability for these patients. Several
studies have shown that AKI biomarkers increase signifi-
cantly in patients with AKI 24e48 hours before an increase
in the SCr level is detectable.38e40 Based on the afore-
mentioned findings, a well-powered trial is required to
examine this issue, which may require an early intervention
guided by novel AKI biomarkers on the 1st day of a patient
on ECMO.38e40Acknowledgments
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